Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Immunization
Reports outline immunization study results from University of Tokyo, Institute of Medical Science
June 4th, 2008
New investigation results, 'Suppression of choroidal neovascularization by vaccination with epitope peptide derived from human VEGF receptor 2 in an animal model,' are detailed in a study published in Investigative Ophthalmology & Visual Science. "It has been shown that vaccination with peptides derived from human vascular endothelial growth factor receptor 2 (VEGFR2) induces cytotoxic T lymphocytes (CTLs) with potent cytotoxicity against endothelial cells expressing VEGFR2 in a A2/Kb transgenic mice system expressing human HLA-A*0201. The present study examined the efficacy of this immunotherapy against age-related macular degeneration (AMD) using a choroidal neovascularization...
Source: Vaccine Weekly (2008-06-04)
|
